Familial Amyotrophic Lateral Sclerosis

Neurology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Ionis Pharmaceuticals
1 program
1
ISIS 333611Phase 11 trial
Active Trials
NCT01041222Completed33Est. Jan 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ionis PharmaceuticalsISIS 333611

Clinical Trials (1)

Total enrollment: 33 patients across 1 trials

Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations

Start: Jan 2010Est. completion: Jan 201233 patients
Phase 1Completed

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space